What's Happening?
PepGen Inc. reported its financial results for the fourth quarter and year-end 2025, highlighting progress in its FREEDOM2 trial for PGN-EDODM1, a treatment for Myotonic Dystrophy Type 1 (DM1). The company observed robust target engagement and splicing
correction in its Phase 1 trial, with plans to report further data in 2026. PepGen is well-funded, with $148.5 million in cash, sufficient to fund operations into 2027.
Why It's Important?
PepGen's advancements in DM1 treatment could offer a new therapeutic option for patients with this serious neuromuscular disease. The company's financial stability supports continued research and development, potentially leading to significant breakthroughs in DM1 treatment. The progress in clinical trials demonstrates the potential of PepGen's EDO platform to deliver effective therapies.
What's Next?
PepGen plans to continue dosing in its FREEDOM2 trial and report data from the 5 mg/kg cohort in early 2026. The company aims to expand its trial to additional countries and address regulatory questions from the FDA. PepGen's focus remains on delivering a meaningful new treatment for the DM1 community.
